These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
51 related articles for article (PubMed ID: 12861476)
1. Inhibitors of hepatitis C--a review of the recent patent literature. Zhang X IDrugs; 2002 Feb; 5(2):154-8. PubMed ID: 12861476 [TBL] [Abstract][Full Text] [Related]
2. The design of a potent inhibitor of the hepatitis C virus NS3 protease: BILN 2061--from the NMR tube to the clinic. Tsantrizos YS Biopolymers; 2004; 76(4):309-23. PubMed ID: 15386268 [TBL] [Abstract][Full Text] [Related]
3. Non-HIV antivirals - a review of the recent patent literature. Combrink K IDrugs; 2002 Aug; 5(8):815-27. PubMed ID: 12802698 [TBL] [Abstract][Full Text] [Related]
4. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection. Njoroge FG; Chen KX; Shih NY; Piwinski JJ Acc Chem Res; 2008 Jan; 41(1):50-9. PubMed ID: 18193821 [TBL] [Abstract][Full Text] [Related]
5. In vitro antiviral activity of SCH446211 (SCH6), a novel inhibitor of the hepatitis C virus NS3 serine protease. Liu R; Abid K; Pichardo J; Pazienza V; Ingravallo P; Kong R; Agrawal S; Bogen S; Saksena A; Cheng KC; Prongay A; Njoroge FG; Baroudy BM; Negro F J Antimicrob Chemother; 2007 Jan; 59(1):51-8. PubMed ID: 17151003 [TBL] [Abstract][Full Text] [Related]
6. Recruitment of an interferon molecular signaling complex to the mitochondrial membrane: disruption by hepatitis C virus NS3-4A protease. Hiscott J; Lacoste J; Lin R Biochem Pharmacol; 2006 Nov; 72(11):1477-84. PubMed ID: 16876765 [TBL] [Abstract][Full Text] [Related]
7. HCV NS3 serine protease-neutralizing single-chain antibodies isolated by a novel genetic screen. Gal-Tanamy M; Zemel R; Berdichevsky Y; Bachmatov L; Tur-Kaspa R; Benhar I J Mol Biol; 2005 Apr; 347(5):991-1003. PubMed ID: 15784258 [TBL] [Abstract][Full Text] [Related]
8. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Lamarre D; Anderson PC; Bailey M; Beaulieu P; Bolger G; Bonneau P; Bös M; Cameron DR; Cartier M; Cordingley MG; Faucher AM; Goudreau N; Kawai SH; Kukolj G; Lagacé L; LaPlante SR; Narjes H; Poupart MA; Rancourt J; Sentjens RE; St George R; Simoneau B; Steinmann G; Thibeault D; Tsantrizos YS; Weldon SM; Yong CL; Llinàs-Brunet M Nature; 2003 Nov; 426(6963):186-9. PubMed ID: 14578911 [TBL] [Abstract][Full Text] [Related]
9. Peptidomimetic therapeutic agents targeting the protease enzyme of the human immunodeficiency virus and hepatitis C virus. Tsantrizos YS Acc Chem Res; 2008 Oct; 41(10):1252-63. PubMed ID: 18681464 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of a diverse set of potential P1 carboxylic acid bioisosteres in hepatitis C virus NS3 protease inhibitors. Rönn R; Gossas T; Sabnis YA; Daoud H; Kerblom E; Danielson UH; Sandström A Bioorg Med Chem; 2007 Jun; 15(12):4057-68. PubMed ID: 17449253 [TBL] [Abstract][Full Text] [Related]
11. Progress and development of small molecule HCV antivirals. Ni ZJ; Wagman AS Curr Opin Drug Discov Devel; 2004 Jul; 7(4):446-59. PubMed ID: 15338954 [TBL] [Abstract][Full Text] [Related]